Evofem Biosciences, Inc. (EVFM) News
Filter EVFM News Items
EVFM News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
EVFM News Highlights
- For EVFM, its 30 day story count is now at 13.
- Over the past 21 days, the trend for EVFM's stories per day has been choppy and unclear. It has oscillated between 1 and 3.
- ACA, ACT and DTC are the most mentioned tickers in articles about EVFM.
Latest EVFM News From Around the Web
Below are the latest news stories about EVOFEM BIOSCIENCES INC that investors may wish to consider to help them evaluate EVFM as an investment opportunity.
Analysts Offer Insights on Healthcare Companies: Evofem Biosciences (OtherEVFM), Greenwich LifeSciences (GLSI) and Chinook Therapeutics (KDNY)There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Evofem Biosciences (EVFM – Research Report), Greenwich LifeSciences (GLSI – Research Report) and Chinook Therapeutics (KDNY – Research Report) with bullish sentiments. Evofem Biosciences (EVFM) In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Evofem Biosciences, with a price target of $4.00. The company's shares closed last Friday at $0.41, close to its 52-week low of $0.28. According to TipRanks. |
Evofem Biosciences to Host Investor Call on Thursday, August 11, 2022Evofem Biosciences, Inc., (EVFM) will hold an investor call as follows: |
Traders News Source Senior Editor, Mark Roberts Interviews Evofem Biosciences, Inc. CEO Saundra PelletierTraders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap publicly traded companies recently issued a new C-Level interview with Evofem Biosciences. |
Evofem Clocks 42% Growth For Its On-Demand Birth Control ProductEvofem Biosciences Inc's (NASDAQ: EVFM) Q2 Phexxi sales increased 42% Y/Y to $6.0 million, reflecting higher ex-factory sales and lower gross-to-net adjustments of 40%. The company's operating expense was reduced by 8% to $30 million and improved loss from operations by 16% to $(24) million. The U.S. government clarified that it would enforce federal law requiring group health plans and health insurance issuers to cover contraception at no cost to participants. In June, Evofem announced an agree |
Evofem Biosciences Announces Strong Second Quarter 2022 Financial Results and Affirms 2022 GuidanceEvofem Biosciences, Inc., (Nasdaq: EVFM) ("Evofem" or the "Company"), today reported financial results for the three- and six-month periods ended June 30, 2022 and affirmed full-year 2022 guidance. |
Evofem Biosciences Strengthens Board of DirectorsEvofem Biosciences, Inc., (Nasdaq: EVFM) today announced the appointment of Jenny Yip, a Managing Partner at life sciences investment fund Adjuvant Capital, to its Board of Directors. The appointment of Ms. Yip as a director expands the Board from five to six independent directors. |
10 Best Penny Stocks to Buy and Hold According to RedditIn this article, we will discuss the 10 best penny stocks to buy and hold according to Reddit. If you want to skip our discussion on the earnings potential of penny stocks, go directly to 5 Best Penny Stocks to Buy and Hold According to Reddit. Penny stocks are subject to fewer regulations for the […] |
Evofem Biosciences Discusses Innovative Woman-Controlled Contraceptive with The Stock Day PodcastPhoenix, Arizona--(Newsfile Corp. - August 1, 2022) - The Stock Day Podcast welcomed Evofem Biosciences (NASDAQ: EVFM) ("the Company"), an innovator in women's sexual and reproductive health and the maker of hormone-free contraceptive Phexxi® (lactic acid, citric acid and potassium bitartrate). Evofem's CEO, Saundra Pelletier, joined Stock Day host Sever Copley. "What is Phexxi and how does it fit into the contraceptive landscape?" asked Copley. "Phexxi is the first and only birth control produc |
Evofem Announces Completion of Last Subject Last Visit (LSLV) in Registrational Phase 3 "EVOGUARD" Trial Evaluating Phexxi® for the Prevention of Chlamydia and Gonorrhea in WomenEvofem Biosciences, Inc., (Nasdaq: EVFM) today announced that the last subject has completed her last visit in EVOGUARD, the Company's registrational Phase 3 trial evaluating the efficacy and safety of Phexxi® (lactic acid, citric acid, potassium bitartrate) for the prevention of chlamydia and gonorrhea infection in women. There are no prescription pharmaceuticals approved to prevent these sexually transmitted infections (STIs). |
Evofem Biosciences Commends Tri-Agencies for Clarifying that Contraceptives Must be Covered at No Cost to IndividualsEvofem Biosciences, Inc., (Nasdaq: EVFM), a women's healthcare company, today commended the U.S. Department of Health and Human Services, alongside the Departments of Labor and of the Treasury ("the Tri-Agencies"), for taking action to clarify protections for birth control coverage under the Affordable Care Act (ACA). |